

Ref: FOI/GS/ID 6243

Please reply to:
 FOI Administrator
 Trust Management
 Maidstone Hospital
 Hermitage Lane
 Maidstone, Kent
 ME16 9QQ
 Email: mtw-tr.foiadmin@nhs.net

20 August 2020

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to ANTI TNF (originator and biosimilar).

You asked:

1 *How many patients (in the Trust) were initiated on ANTI TNF (originator and biosimilar) over the last 12 months?*

2 *How many patients (in the Trust) have been initiated on biosimilar adalimumab?*

• *and what is the split by brand in the last 12 months for the following products?*

- o Amgevita*
- o Imraldi*
- o Hulio*
- o Hyrmioz*
- o Idacio*

3 *How many patients have been initiated on these products?*

- o guselkumab (Tremfya)*
- o risankizumab (Skyrizi)*
- o brodalumab (Kyntheum)*
- o ixekizumab (Taltz)*

Trust response:

Please see the following table.

1	How many patients (in the Trust) were initiated on ANTI TNF (originator and biosimilar) over the last 12 months?	172
---	--	-----

2	How many patients (in the Trust) have been initiated on biosimilar adalimumab?	99
2a.	and what is the split by brand in the last 12 months for the following products?	
	o Amgevita	1
	o Imraldi	98
	o Hulio	0
	o Hyrmioz	0
	o Idacio	0
3	How many patients have been initiated on these products?	
	o guselkumab (Tremfya)	0
	o risankizumab (Skyrizi)	0
	o brodalumab (Kyntheum)	0
	o ixekizumab (Taltz)	2